28June

Oral semaglutide shows superior reductions in HbA1c and weight compared to sitag ... Read more

23June

Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in ... Read more

23June

Ozempic® provided greater weight reductions for adults with a baseline BMI of or ... Read more

23June

Tresiba® demonstrated significantly improved blood sugar control and lower rates ... Read more

16July

Novo Nordisk A/S - Share repurchase programme ... Read more

09July

Novo Nordisk A/S - Share repurchase programme ... Read more

02July

Novo Nordisk A/S - Share repurchase programme ... Read more

28June

Oral semaglutide shows superior reductions in HbA1c and weight compared to sitag ... Read more

08August

Financial statement for the first six months of 2018,

23August

Deutsche Bank Scandinavian Corporate Day , Helsinki

28August

Commerzbank Sector Conference, Frankfurt

05September

ABG Sundal Collier Large Cap Seminar , Copenhagen

 

 

 

Investors

 
Share information


Take an advanced view of the Novo Nordisk share

 
Annual Report 2017 


Click here to find further information

 
Q2 2018 financial results


Novo Nordisk at a glance


Private shareholders


See relevant content for private investors



IR material


Download relevant Investor Relations material



Contacts



Subscriptions


Sign up to receive company announcements.


ADA investor and analyst event